Emerging drugs for varicella-zoster virus infections (Q34027426)

30 July 2017

1 reference

title

Emerging drugs for varicella-zoster virus infections (English)

1 reference

30 July 2017

Robert Snoeck

2

0 references

Graciela Andrei

object named as

Graciela Andrei

series ordinal

1

0 references

language of work or name

English

0 references

publication date

24 June 2011

1 reference

Expert Opinion on Emerging Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

16

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

507-535

1 reference

Advances in the understanding of the pathogenesis and epidemiology of herpes zoster

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Disseminated varicella with multiorgan failure in an immunocompetent adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Varicella Hepatitis: A Fatal Case in a Previously Healthy, Immunocompetent Adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Disseminated varicella zoster virus in an immunized child as the acquired immunodeficiency syndrome-defining illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Persistent verrucous varicella as the initial manifestation of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Fulminant hepatitis and death associated with disseminated varicella in an immunocompromised adult from the Czech Republic caused by a wild-type clade 4 varicella-zoster virus strain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Postherpetic neuralgia in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

The impact of herpes zoster and post-herpetic neuralgia on quality-of-life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

The impact of varicella zoster virus: chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Zoster in patients infected with HIV: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Acute retinal necrosis: clinical features, early vitrectomy, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Progressive outer retinal necrosis syndrome: a comprehensive review of its clinical presentation, relationship to immune system status, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Progressive outer retinal necrosis in the era of highly active antiretroviral therapy: successful management with intravitreal injections and monitoring with quantitative PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Progressive outer retinal necrosis in immunocompetent patients treated initially for optic neuropathy with systemic corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Impact of varicella vaccine on varicella-zoster virus dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Varicella vaccine and infection with varicella-zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Varicella infections and varicella vaccine in the 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Vaccine Oka variants and sequence variability in vaccine-related skin lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Vaccination to prevent herpes zoster in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Prevention strategies for herpes zoster and post-herpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Once-daily valacyclovir to reduce the risk of transmission of genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

(E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Antiviral therapy of herpes simplex and varicella-zoster virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Management of herpes zoster and post-herpetic neuralgia now and in the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

The safety profile of varicella vaccine: a 10-year review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Vaccine-strain varicella zoster virus causing recurrent herpes zoster in an immunocompetent 2-year-old

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

VZV meningitis following varicella vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Vaccine-associated herpes zoster ophthalmicus [correction of opthalmicus] and encephalitis in an immunocompetent child

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Meningoradiculoneuritis due to acyclovir-resistant varicella zoster virus in an acquired immune deficiency syndrome patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Foscarnet Therapy in Five Patients with AIDS and Acyclovir-resistant Varicella-Zoster Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Acyclovir-resistant chronic verrucous vaccine strain varicella in a patient with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella-zoster virus to PCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Development of Resistance to Acyclovir during Chronic Infection with the Oka Vaccine Strain of Varicella‐Zoster Virus, in an Immunosuppressed Child

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of terminal unsaturation in the side chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of a terminal halogen substitution in the side-chain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Bicyclic anti-VZV nucleosides: Thieno analogues retain full antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Anti-varicella-zoster virus bicyclic nucleosides: replacement of furo by pyrro base reduces antiviral potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Synthesis and anti-varicella-zoster virus activity of some novel bicyclic nucleoside inhibitors: effect of enhanced aqueous solubility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Metabolic and pharmacological characteristics of the bicyclic nucleoside analogues (BCNAs) as highly selective inhibitors of varicella-zoster virus (VZV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Discovery of a novel series of inhibitors of human cytomegalovirus primase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Activity of H2G on human herpesvirus-6B strains either sensitive or resistant to ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Thiourea inhibitors of herpes viruses. Part 2: N-Benzyl-N'-arylthiourea inhibitors of CMV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Amphipathic DNA polymers exhibit antiherpetic activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Amphipathic DNA Polymers Inhibit Hepatitis C Virus Infection by Blocking Viral Entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Acyclic nucleoside phosphonates: a key class of antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Papillomavirus and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Inhibition of herpesvirus replication by a series of 4-oxo-dihydroquinolines with viral polymerase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Design and development of oral drugs for the prophylaxis and treatment of smallpox infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Synthesis and antiviral evaluation of alkoxyalkyl esters of phosphonopropoxymethyl-guanine and phosphonopropoxymethyl-diaminopurine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

The acyclic nucleoside phosphonates from inception to clinical use: historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

6-[2-phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Synthesis and antiviral activity of 2,4-diamino-5-cyano-6-[2-(phosphonomethoxy)ethoxy]pyrimidine and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Activities of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Cyclin-dependent kinases as cellular targets for antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Pharmacological cdk inhibitor R-Roscovitine suppresses JC virus proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Simian varicella virus infection of rhesus macaques recapitulates essential features of varicella zoster virus infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

DNA Sequence Variability in Oka Vaccine Isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

Comparative Efficacy of Famciclovir and Valacyclovir for Suppression of Recurrent Genital Herpes and Viral Shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.591786

10.1517/14728214.2011.591786

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference